Journal Mobile Options
Table of Contents
Vol. 21, No. 5, 2006
Issue release date: August 2006
Fetal Diagn Ther 2006;21:404–409

Non-Invasive Detection of Fetal Rhesus D Status: A Comparison between Polymerase Chain Reaction and Flow Cytometry

Di Simone N. · Lai M. · Rumi C. · Riccardi P. · D’Asta M. · Leone G. · Mancuso S. · Caruso A.
Departments of aObstetrics and Gynecology and bHematology, Catholic University of the Sacred Heart, Rome, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: A non-invasive prenatal determination of the fetal RhD status might be useful for the management of pregnancies in RhD-negative women whose partners are RhD positive. Methods: Maternal peripheral blood of 32 RhD-negative women (17–24 weeks of gestation) was collected, and circulating fetal cells were enriched by CD71 mini-magnetic activated cell sorting. The RhD status of the fetuses was assessed using multiparametric flow cytometry, and results were compared to those of reverse transcriptase (RT)-polymerase chain reaction (PCR), or PCR, which acted as control. Flow-cytometric study of fetal cells employed monoclonal antibodies directed against CD71, glycophorin A (GPA) and RhD antigens. Results: The median percentage of CD71- and RhD-positive cells was 0.83% (range 0.14–6.44%), and that of CD71 and GPA-positive cells was 10.07% (range 0.52–45.84%). Flow-cytometric analysis correlated with RT-PCR results of RNA obtained from whole maternal blood. In 1 case, an incorrect result was due to the failure of the amplification of the specific RhD band on RNA extracted from the CD71-positive fraction. In two instances, we observed false-positive results for RhD in PCR of DNA obtained from maternal plasma. Conclusion: Based on our results, flow-cytometric analysis might be proposed as a clinical tool for the non-invasive prenatal determination of the fetal RhD status independently of fetal gender.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999;66:63–70.
  2. Fisk NM, Bennett P, Warwick RM, Letsky EA, Welch R, Vaughan JI, Moore G: Clinical utility of fetal RhD typing in alloimmunized pregnancies by means of polymerase chain reaction on amniocytes or chorionic villi. Am J Obstet Gynecol 1994;171:50–54.
  3. Crombach G, Niederacher D, Larbig D, Picard F, Tutschek B, Beckmann MW, Bender HG: Reliability and clinical application of fetal RhD genotyping with two different fluorescent duplex polymerase chain reaction assays: three years’ experience. Am J Obstet Gynecol 1999;180:435–440.
  4. Chan FY, Cowley NM, Wolter L, Stone M, Carmody F, Saul A, Hyland CA: Prenatal RhD gene determination and dosage analysis by PCR: clinical evaluation. Prenat Diagn 2001;21:321–326.
  5. Aubin JT, Le Van Kim C, Mouro I, Colin Y, Bignozzi C, Brossard Y, Cartron JP: Specificity and sensitivity of RhD genotyping methods by PCR-based DNA amplification. Br J Haematol 1997;98:356–364.
  6. Maaskant-van Wijk PA, Faas BH, de Ruijter JA, Overbeeke MA, von dem Borne AE, van Rhenen DJ, van der Schoot CE: Genotyping of RhD by multiplex polymerase chain reaction analysis of six RhD-specific exons. Transfusion 1998;38:1015–1021.
  7. Raptis L, Menard HA: Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J ClinInvest 1980;66:1391–1399.
  8. Lo YMD, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PMK: Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768–775.
  9. Van Wijk IJ, de Hoon AC, Jurhawan R, Tjoa ML, Griffioen S, Mulders MA, van Vugt JM, Oudejans CB: Detection of apoptotic fetal cells in plasma of pregnant women. Clin Chem 2000;46:729–731.
  10. Legler TJ, Lynen R, Maas JH, Pindur G, Kulenkampff D, Suren A, Osmers R, Kohler M: Prediction of fetal RhD and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apher Sci 2002;27:217–223.
  11. Lo YMD, Bowell PJ, Selinger M, MacKenzie IZ, Chamberlain P, Gillmer MD, Littlewood TJ, Fleming KA, Wainscoat JS: Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers. Lancet 1993;341:1147–1148.
  12. Geifman-Holtzman O, Bernstein IM, Berry SM, Holtzman EJ, Vadnais TJ, DeMaria MA, Bianchi DW: Fetal RhD genotyping in fetal cells flow sorted from maternal blood. Am J Obstet Gynecol 1996;174:818–822.
  13. Sekizawa A, Watanabe A, Kimura T, Saito H, Yanaihara T, Sato T: Prenatal diagnosis of the fetal RhD blood type using a single fetal nucleated erythrocyte from maternal blood. Obstet Gynecol 1996;87:501–505.
  14. Cha D, Hogan B, Bohmer RM, Bianchi DW, Johnson KL: A simple and sensitive erythroblast scoring system to identify fetal cells in maternal blood. Prenat Diagn 2003;23:68–73.
  15. Miny P, Tercanli S, Holzgreve W: Developments in laboratory techniques for prenatal diagnosis. Curr Opin Obstet Gynecol 2002;14:161–168.
  16. Prieto B, Candenas M, Ladenson JH, Alvarez FV: Comparison of different CD71 monoclonal antibodies for enrichment of fetal cells from maternal blood. Clin Chem Lab Med 2002;40:126–131.
  17. Troeger C, Holzgreve W, Hahn S: A comparison of different density gradients and antibodies for enrichment of fetal erythroblasts by MACS. Prenat Diagn 1999;19:521–526.
  18. Wachtel SS, Shulman LP, Sammons D: Fetal cells in maternal blood. Clin Genet 2001;59:74–79.
  19. Price J, Elias S, Wachtel S: Prenatal diagnosis using fetal cells isolated from maternal blood by multiparameter flow cytometry. Am J Obstet Gynecol 1999;165:1731–1737.
  20. Bischoff FZ, Hahn S, Johnson KL, Simpson JL, Bianchi DW, Lewis DE, Weber WD, Klinger K, Elias S, Jackson LG, Evans MI, Holzgreve W, de la Cruz F: Intact fetal cells in maternal plasma: are they really there? Lancet 2003;361:139–140.
  21. Sekizawa A, Samura O, Zhen D, Falco V, Farina A, Bianchi DW: Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. PrenatDiagn 2000;20:886–889.
  22. Choolani M, O’Donoghue K, Talbert D, Kumar S, Roberts I, Letsky E, Bennet PR, Fisk NM: Characterization of first trimester fetal erythroblasts for non-invasive prenatal diagnosis. Mol Hum Reprod 2003;9:227–235.
  23. Babochkina T, Mergenthaler S, De Napoli G, Hristoskova S, Tercanli S, Holzgreve W, Hahn S: Numerous erythroblasts in maternal blood are impervious to fluorescent in situ hybridization analysis, a feature related to a dense compact nucleus with apoptotic character. Haematologica. 2005;90:740–745.

    External Resources

  24. Costa JM, Giovangrandi Y, Ernault P, Lohmann L, Nataf V, El Halali N, Gautier E: Fetal RhD genotyping in maternal serum during the first trimester of pregnancy. Br J Haematol 2002;119:255–260.
  25. Daniels G, Green C, Smart E: Differences between RhD-negative Africans and RhD-negative Europeans. Lancet 1997;350:862–863.
  26. Okuda H, Kawano M, Iwamoto S, Tanaka M, Seno T, Okubo Y, Kajii E: The RhD gene is highly detectable in RhD-negative Japanese donors. J ClinInvest 1997;100:373–379.
  27. Wagner FF, Frohmajer A, Flegel WA: RhD positive haplotypes in D negative Europeans. BMC Genet 2001;2:10–18.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50